[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "fullTimeEmployees": 68, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Harvey Davidson FACC, Facp., M.D.", "age": 68, "title": "CEO, President & Executive Board Member", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 1122237, "exercisedValue": 0, "unexercisedValue": 51427864}, {"maxAge": 1, "name": "Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.", "age": 70, "title": "Founder, Chief Scientific Officer, Member of Executive Board & Director", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 813077, "exercisedValue": 4094829, "unexercisedValue": 35092304}, {"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 841238, "exercisedValue": 0, "unexercisedValue": 3954412}, {"maxAge": 1, "name": "Mr. Douglas F. Kling", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 913742, "exercisedValue": 0, "unexercisedValue": 17441960}, {"maxAge": 1, "name": "Ms. Juliette  Audet M.B.A., M.Sc.", "age": 37, "title": "Chief Strategy & Business Officer", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 653039, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Louise  Kooij", "age": 48, "title": "Chief Accounting Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Philippe", "title": "Executive VP &Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  Rambo", "title": "Executive Vice President of Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maryellen  McQuade", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Ditmarsch M.D.", "age": 57, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 25.66, "open": 25.58, "dayLow": 25.16, "dayHigh": 27.046, "regularMarketPreviousClose": 25.66, "regularMarketOpen": 25.58, "regularMarketDayLow": 25.16, "regularMarketDayHigh": 27.046, "payoutRatio": 0.0, "beta": -0.007, "forwardPE": -14.285714, "volume": 1501443, "regularMarketVolume": 1501443, "averageVolume": 889911, "averageVolume10days": 862270, "averageDailyVolume10Day": 862270, "bid": 26.89, "ask": 27.05, "bidSize": 2, "askSize": 2, "marketCap": 3040955904, "fiftyTwoWeekLow": 14.06, "fiftyTwoWeekHigh": 27.29, "priceToSalesTrailing12Months": 47.510483, "fiftyDayAverage": 22.842, "twoHundredDayAverage": 21.3257, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2302134272, "profitMargins": -2.58905, "floatShares": 54895110, "sharesOutstanding": 112628000, "sharesShort": 7328645, "sharesShortPriorMonth": 6878437, "sharesShortPreviousMonthDate": 1752537600, "dateShortInterest": 1755216000, "sharesPercentSharesOut": 0.0651, "heldPercentInsiders": 0.00385, "heldPercentInstitutions": 1.07052, "shortRatio": 9.09, "shortPercentOfFloat": 0.0776, "impliedSharesOutstanding": 112628000, "bookValue": 6.919, "priceToBook": 3.902298, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -165715008, "trailingEps": -1.59, "forwardEps": -1.89, "enterpriseToRevenue": 35.967, "enterpriseToEbitda": -13.337, "52WeekChange": 0.59952605, "SandP52WeekChange": 0.18469036, "quoteType": "EQUITY", "currentPrice": 27.0, "targetHighPrice": 45.358738, "targetLowPrice": 27.199299, "targetMeanPrice": 40.85121, "targetMedianPrice": 41.801292, "recommendationMean": 1.38462, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 12, "totalCash": 739161984, "totalCashPerShare": 6.563, "ebitda": -172616000, "totalDebt": 328000, "quickRatio": 20.785, "currentRatio": 21.085, "totalRevenue": 64006000, "debtToEquity": 0.042, "revenuePerShare": 0.597, "returnOnAssets": -0.17118, "returnOnEquity": -0.28426, "grossProfits": 64006000, "freeCashflow": -85028000, "operatingCashflow": -124122000, "revenueGrowth": 7.401, "grossMargins": 1.0, "ebitdaMargins": -2.69687, "operatingMargins": -1.86132, "financialCurrency": "USD", "symbol": "NAMS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "NewAmsterdam Pharma Company N.V", "longName": "NewAmsterdam Pharma Company N.V.", "corporateActions": [], "postMarketTime": 1757108371, "regularMarketTime": 1757102400, "exchange": "NGM", "messageBoardId": "finmb_685404834", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 5.22214, "regularMarketPrice": 27.0, "marketState": "CLOSED", "ipoExpectedDate": "2022-11-23", "prevName": "Frazier Lifesciences Acquisition Corporation", "nameChangeDate": "2025-09-05", "averageAnalystRating": "1.4 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612881000000, "postMarketChangePercent": 0.0, "postMarketPrice": 27.0, "postMarketChange": 0.0, "regularMarketChange": 1.34, "regularMarketDayRange": "25.16 - 27.046", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 889911, "fiftyTwoWeekLowChange": 12.94, "fiftyTwoWeekLowChangePercent": 0.9203413, "fiftyTwoWeekRange": "14.06 - 27.29", "fiftyTwoWeekHighChange": -0.29000092, "fiftyTwoWeekHighChangePercent": -0.010626636, "fiftyTwoWeekChangePercent": 59.952606, "earningsTimestamp": 1754539200, "earningsTimestampStart": 1762345800, "earningsTimestampEnd": 1762345800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.59, "epsForward": -1.89, "epsCurrentYear": -1.19567, "priceEpsCurrentYear": -22.581482, "fiftyDayAverageChange": 4.158001, "fiftyDayAverageChangePercent": 0.18203315, "twoHundredDayAverageChange": 5.6742992, "twoHundredDayAverageChangePercent": 0.26607797, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "displayName": "NewAmsterdam Pharma Company", "trailingPegRatio": null, "__fetch_time": "2025-09-06"}]